Biogen Idec, a drug developing company, has recently discontinued their work on a new drug that was, hopefully, going to help patients with Amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease. A recent article explained that a new drug, known as dexpramipexole, was not effective in the phase 3 trial of the study.
Amyotrophic lateral sclerosis (ALS) is a disease where nerve cells “waste away and die.” These cells are unable to send messages to muscles, therefore symptoms include paralysis and muscle weakness. The progression of the disease is slow and “once the patient loses the function of muscles in the chest area, it becomes hard to breathe.” There is no known cure for this disease but scientists are looking for ways to prolong the disease.
Biogen Idec believed that the drug, dexpramipexole, was hopefully going to “slow the progression of loss of muscle function and prolong the lives of people with the disease.” While the phase 3 trial was not successful, the phase 2 trial of patients receiving dexpramipexole showed some success. 50% of the patients, in the second trial, showed a slower decline of muscular function. This was a big accomplishment for Biogen Idec but the phase 3 was not as effective. Therefore, Biogen Idec’s study involving a new treatment for ALS ended.
Even though Biogen Idec’s study was not effective, other companies have successfully found a way to slow the progression of ALS. Thus far, only one drug has been approved to help patients with ALS. This drug is known as Rilutek/Riluzole and it is only modestly effective.
Doctors are in need of a new drug that will help patients with ALS. I think its great that companies like Biogen Idec are involved in finding a way to treat this rare disease. I hope that researchers will use the information from the failed trial to find another way to treat ALS.